医学
银屑病
不利影响
最后
临床试验
安慰剂
银屑病面积及严重程度指数
皮肤病科
内科学
药理学
病理
替代医学
银屑病性关节炎
作者
Nickoulet Babaei,Dahyeon Kim,Mireya Cervantes,Seanna Yang,Minka Gill,Jashin J. Wu
摘要
Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, represents a novel approach to systemic psoriasis treatment, offering the advantages of oral administration and selective inhibition of cytokine signaling pathways involved in psoriasis pathogenesis. This review evaluates the efficacy and safety of deucravacitinib based on findings from phase III clinical trials, including POETYK PSO-1, PSO-2, PSO-4, and long-term extension studies. In these trials, deucravacitinib demonstrated superior efficacy compared to placebo and apremilast, with a significantly higher proportion of patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75). Long-term data suggest sustained efficacy through 3 years of continuous treatment. Deucravacitinib was well tolerated, with a safety profile characterized by low rates of serious adverse events, including infections and major cardiovascular events. The most common adverse events included nasopharyngitis, upper respiratory tract infections, and acne, with herpes zoster occurring at a low incidence. The results of the phase III trials support deucravacitinib as an effective oral alternative to biologic therapies, with sustained efficacy and a favorable safety profile. Future studies should explore head-to-head comparisons with interleukin (IL)-17 and IL-23 inhibitors to define their role in psoriasis management better.
科研通智能强力驱动
Strongly Powered by AbleSci AI